# Stellaromics Inc.

> Stellaromics is a Boston-based spatial biology company building tools that map gene expression in three dimensions inside intact tissue. Spun out of the labs of Karl Deisseroth (Stanford) and Xiao Wang (MIT/Broad Institute), the company commercializes its Pyxa platform, which uses proprietary STARmap and RIBOmap chemistry to deliver multiplexed 3D spatial transcriptomics and translatomics in tissue sections up to 100 microns thick at subcellular resolution. It targets researchers in neuroscience, oncology and immunology who need to preserve native tissue architecture rather than rely on flat 2D thin-section methods.

- **Founded:** 2022
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Ye Fu (Co-Founder & Chief Scientific Officer), Xiao Wang (Scientific Co-Founder (MIT / Broad Institute)), Karl Deisseroth (Scientific Co-Founder (Stanford University))
- **Team size:** ~58 employees
- **Products:** Pyxa, STARmap, RIBOmap
- **Notable:** Launched Pyxa at AGBT 2025 as the first commercial platform for 3D spatial multi-omics in intact tissue., Raised $105M total across Series A ($25M) and Series B ($80M)., Commercialized STARmap and RIBOmap technologies originally published in Science, Nature and Cell.

## Products & services

- **Pyxa** — Commercial platform for True 3D spatial multi-omics, delivering multiplexed 3D spatial transcriptomics in intact tissue up to 100 microns thick. Integrates sample preparation, automated volumetric confocal imaging, and data analysis/visualization; processes up to 12 wells simultaneously.
- **STARmap** — Spatially-resolved Transcript Amplicon Readout Mapping - proprietary in situ sequencing chemistry that measures gene expression within intact tissue at single-molecule, subcellular resolution.
- **RIBOmap** — Ribosome-bound mRNA mapping technology that captures translation (which genes are actively being made into protein) in situ, extending spatial analysis beyond transcription to translatomics.

## Achievements

- Launched Pyxa at AGBT 2025 as the first commercial platform for 3D spatial multi-omics in intact tissue.
- Raised $105M total across Series A ($25M) and Series B ($80M).
- Commercialized STARmap and RIBOmap technologies originally published in Science, Nature and Cell.
- Established first US Pyxa site at UC Irvine and expanded beta program to Emory University.
- Early access program fully subscribed ahead of commercial launch.

## Latest updates

- **2025-02** — Closed $80M Series B led by Catalyst4 with Stanford University Ventures to commercialize Pyxa.
- **2025-02** — Launched Pyxa at AGBT, billed as the first commercial 3D spatial multi-omics platform for intact tissue.
- **2025** — Established first US Pyxa 3D spatial transcriptomics site at UC Irvine.
- **2025** — Expanded Pyxa beta program with installation at Emory University School of Medicine.

## Links

- Website: https://stellaromics.com
- LinkedIn: https://www.linkedin.com/company/stellaromics
- Twitter/X: https://twitter.com/stellaromics
- YouTube: https://www.youtube.com/@stellaromics
- Bluesky: https://bsky.app/profile/stellaromics.bsky.social

---

Profile page: https://yespress.io/stellaromics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18